Sultan Qaboos University received a new patent for the invention based on ” Therapeutic composition for treating gangrene” invented by Dr. Sidgi Syed Anwar Abdo Hasson and Prof. Ali Abdullah Hassan Al-Jabri from the Department of Microbiology and Immunology, College of Medicine & Health Sciences. The patent application for this invention was filed on 16/10/2017 and granted from the United States – USPTO. The invention relates to treatment of dry and wet gangrene, and particularly to a method of making a therapeutic tropical plants and camel products-based composition for the treatment of gangrene.
Commenting on their work, the inventors said that the invention is a scientific breakthrough resulted from several years of continuous research work involving a wide range of scientific research disciplines. It relates to a novel treatment for dry and wet gangrene.
Gangrene is a serious condition in which a loss of blood supply causes body tissue to die. It can affect any part of the body but typically starts in the toes, feet, fingers and hands.
The management of gangrene differs according to whether it is sterile/aseptic (dry) or infected/septic (wet). Surgical removal of dead tissues and amputation are usually reserved for infected or septic wet gangrene as a result of infection in immune-compromised patients with diabetes. Despite efficacious anti-microbial treatment and improved supportive measures, “wet” gangrene treatment still poses immense challenges and is usually regarded as ‘incurable’. Although various therapies for the treatment are available, however, such therapies are quite often, unable to treat wounds leads to amputation of the infected limbs. Thus, a therapy for wet and dry gangrene solving the aforementioned problems is desired.
Although it is in its preliminary clinical trial, this new medicament formula could potentially be purposed as a treatment for wet and dry gangrene medication, according to encouraging data from the preclinical trial.
The drug formula composition consist three elements (i) a mixture of three extracts of tropical herbs, (ii) camels milk and (iii) camels saliva. The camel milk is harvested from a camel that is fed the herbal composition mixed with camel saliva at adequate concentration.
The therapeutic composition also found to regenerate damaged tissue as well as bone marrow stem cells in both animal and human. The composition is effective in curing non-healing wounds of diabetics and “wet” gangrene. The therapeutic composition can also be used to treat wounds, skin ulcers, necrosis and burns.
The method for treating “wet” and “dry” gangrene, include administering to a patient in need an effective amount of the therapeutic composition under close medical supervision. The therapeutic composition is administered both orally and topically.
The composition exhibits remarkable efficacy in treating and curing acute “wet” gangrene, which is generally regarded as ‘incurable’ and mostly requires limb amputation. The novel strategy of using camel as a manufacturer vehicle could open research gates for other clinical complications treatments.
The rational of the current invention was, therefore, to search for agent(s) that fulfil the incurable state associated with wet gangrene clinical complications. Hence, this invention may also be applicable against other clinical complications as stated above, the inventors said.